AZRX AzurRx BioPharma, Inc. Stock Quote

publish chart | save to portfolio | create alert

Settings

AZRX [NASD]

AzurRx BioPharma, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	11.09%	Shs Outstand	28.52M	Perf Week	2.11%
Market Cap	24.34M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	27.04M	Perf Month	9.01%
Income	-24.70M	PEG	-	EPS next Q	-0.14	Inst Own	5.20%	Short Float	0.23%	Perf Quarter	-2.28%
Sales	-	P/S	-	EPS this Y	22.80%	Inst Trans	11.06%	Short Ratio	0.43	Perf Half Y	-12.94%
Book/sh	0.49	P/B	1.62	EPS next Y	42.30%	ROA	-243.00%	Target Price	-	Perf Year	10.59%
Cash/sh	0.37	P/C	2.13	EPS next 5Y	-	ROE	-472.30%	52W Range	0.37 - 1.94	Perf YTD	-23.80%
Dividend	-	P/FCF	-	EPS past 5Y	-22.50%	ROI	-	52W High	-59.93%	Beta	1.75
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	-	Gross Margin	-	52W Low	109.43%	ATR	0.04
Employees	10	Current Ratio	4.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.76	Volatility	3.99% 5.85%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-181.20%	Profit Margin	-	Rel Volume	0.41	Prev Close	0.79
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	146.31K	Price	0.78
Recom	2.00	SMA20	4.50%	SMA50	3.27%	SMA200	-2.24%	Volume	59,417	Change	-1.99%

Jun-11-19

Initiated

National Securities

Buy

Oct-17-18

Initiated

Oppenheimer

Outperform

Jul-24-17

Initiated

H.C. Wainwright

Buy

Nov-30-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Nov-24-20 08:17AM	InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein GlobeNewswire
Nov-17-20 08:00AM	AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients GlobeNewswire
Nov-10-20 08:00AM	AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production GlobeNewswire
Oct-29-20 12:05PM	AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives GlobeNewswire -5.05%
Oct-21-20 08:00AM	AzurRx BioPharma Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-14-20 08:00AM	AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Oct-07-20 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Sep-15-20 08:00AM	AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire +6.94%
Aug-31-20 06:12PM	LD Micro: 360 Companies - Set to Present this Week ACCESSWIRE
08:00AM	AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4) GlobeNewswire
Aug-26-20 06:42AM	AZRX: 1H:21 Readout for OPTION 2 and Combo Trials Zacks Small Cap Research -5.66%
Aug-17-20 08:00AM	AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Aug-13-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire -12.39%
Aug-12-20 03:43PM	AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders GlobeNewswire +9.88%
12:20PM	AZRX: MS1819 Update: Interim Data Zacks Small Cap Research
07:29AM	The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private Benzinga
Aug-11-20 04:01PM	AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +7.97%
Aug-05-20 11:04AM	LD Micro Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Jul-27-20 05:22AM	AZRX: Capital Raise, OPTION 2 Trial Underway Zacks Small Cap Research
Jul-22-20 08:20AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire +9.52%
08:00AM	AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis with First Patient Screened and Three Clinical Trial Sites Activated GlobeNewswire
Jul-21-20 08:00AM	Alexander Capital, L.P. Congratulates AzurRx BioPharma on $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire +8.25%
Jul-20-20 08:00AM	AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire
Jun-01-20 05:45AM	AZRX: Next Up: OPTION 2 Zacks Small Cap Research
May-29-20 03:08PM	Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX) Insider Monkey
May-07-20 08:00AM	AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product GlobeNewswire
May-05-20 08:00AM	AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit) GlobeNewswire
May-04-20 06:45AM	What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)? Simply Wall St. +8.30%
Apr-30-20 08:00AM	AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Apr-29-20 08:00AM	AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites GlobeNewswire
Apr-21-20 08:00AM	AzurRx BioPharma Issues Letter to Shareholders GlobeNewswire -9.16%
Apr-20-20 08:00AM	Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX) GlobeNewswire
Apr-16-20 02:00PM	AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product GlobeNewswire +17.24%
Apr-15-20 08:00AM	AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE -6.45%
Apr-09-20 10:30AM	AzurRx Appoints Gregory Oakes to its Board of Directors GlobeNewswire +8.93%
06:50AM	AZRX: Tax Credits Augment Cash Flow Zacks Small Cap Research
Apr-01-20 12:00PM	AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit) GlobeNewswire
Mar-18-20 08:00AM	AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th ACCESSWIRE
Mar-02-20 08:00AM	AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) GlobeNewswire -5.08%
Feb-18-20 08:00AM	AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference GlobeNewswire
Feb-03-20 10:10AM	AZRX: EPI Treatment in the News Zacks Small Cap Research +9.99%
Jan-13-20 08:00AM	AzurRx BioPharma Announces Closing of $6.9 Million Private Placement GlobeNewswire
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO Benzinga
Jan-09-20 07:22PM	AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco GlobeNewswire +18.33%
Jan-06-20 08:00AM	AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th) GlobeNewswire
Jan-03-20 08:00AM	AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer GlobeNewswire
Nov-26-19 11:35AM	AZRX: 3Q:19 Review Zacks Small Cap Research -5.07%
Nov-14-19 08:00AM	AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC GlobeNewswire +26.98%
Oct-22-19 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Oct-17-19 12:30PM	AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data GlobeNewswire +24.71%
Oct-15-19 07:30AM	AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +23.36%
Oct-10-19 07:30AM	AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer GlobeNewswire -9.94%
Sep-27-19 08:30AM	AZRX: OPTION Trial Readout Zacks Small Cap Research -11.06%
Sep-25-19 08:57AM	AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency Benzinga -21.00%
07:30AM	AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients GlobeNewswire
Aug-28-19 01:15PM	What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.
Aug-26-19 11:30AM	AZRX: OPTION & Combo Trial Underway Zacks Small Cap Research
Aug-13-19 07:00AM	AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-22-19 08:01PM	AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock ACCESSWIRE
Jul-17-19 11:35PM	AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock ACCESSWIRE
04:44PM	AzurRx BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-10-19 10:45AM	AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI Zacks Small Cap Research +5.69%
Jul-08-19 04:03PM	AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET GlobeNewswire -13.79%
04:01PM	AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Jun-07-19 08:00AM	AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers GlobeNewswire
May-28-19 08:22AM	How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-23-19 09:45AM	AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients Zacks Small Cap Research
08:00AM	AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial GlobeNewswire
May-20-19 02:30PM	AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference GlobeNewswire
Apr-23-19 07:45AM	AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial GlobeNewswire
Apr-11-19 10:00AM	AZRX: CF Study Up and Enrolling; Target to $8 Zacks Small Cap Research
Apr-02-19 07:45AM	Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights GlobeNewswire
Mar-18-19 07:45AM	AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference GlobeNewswire
Mar-15-19 07:45AM	AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20) GlobeNewswire +7.37%
Mar-12-19 07:45AM	AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting GlobeNewswire
Feb-20-19 07:45AM	AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial GlobeNewswire +18.24%
Jan-21-19 11:52AM	What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.
Dec-19-18 08:00AM	AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients GlobeNewswire
Dec-12-18 08:00AM	AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group GlobeNewswire
Dec-04-18 09:45AM	AZRX: 3Q:18 Financial and Operational Summary Zacks Small Cap Research
08:00AM	AzurRx BioPharma to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 07:30AM	AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI GlobeNewswire +8.60%
Oct-16-18 07:30AM	AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis GlobeNewswire
Sep-24-18 03:45PM	AZRX: Final Results from Phase II EPI Trial Zacks Small Cap Research +11.32%
07:45AM	AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis GlobeNewswire
Aug-28-18 09:45AM	AZRX: Phase 2 Cystic Fibrosis Study to Start Zacks Small Cap Research
08:30AM	AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th GlobeNewswire
Aug-01-18 08:30AM	AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th) GlobeNewswire -6.27%
Jul-02-18 09:30AM	AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial Zacks Small Cap Research
Jun-29-18 08:30AM	AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency GlobeNewswire +5.59%
May-30-18 08:03AM	AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer GlobeNewswire
May-02-18 11:15AM	AZRX: AzurRx Raises Capital After Confirming Results Zacks Small Cap Research +8.05%
May-01-18 09:10AM	AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock GlobeNewswire -7.74%
07:51AM	Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 04:15PM	AzurRx BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-23-18 08:45AM	AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI) GlobeNewswire -11.92%
Apr-18-18 07:45AM	AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 GlobeNewswire
Apr-13-18 01:15PM	AZRX: French Sites to Help Achieve 1H:18 Enrollment Goal Zacks Small Cap Research +10.86%
Mar-02-18 09:00AM	Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC ACCESSWIRE

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience